{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-250223","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.235026+00:00","generated_at":"2026-05-30T05:50:34.492958+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch","bullets":["Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.","Tiered royalties: 5% on net sales up to $500M, 1.1% on $500M-$750M, 0.25% above $750M; rate increases if optional payment taken.","Additional $22M optional if US approval by Sep 30, 2025; PDUFA date June 17, 2025 for sebetralstat (oral HAE therapy).","DRI expressed non-binding interest in up to $5M private placement of KalVista common stock.","Royalty financing non-dilutive; proceeds to fund commercial launch of sebetralstat."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-250223","json":"https://secwatch.observer/filing/0001193125-24-250223.json","markdown":"https://secwatch.observer/filing/0001193125-24-250223.md","text":"https://secwatch.observer/filing/0001193125-24-250223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/0001193125-24-250223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/d904891d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:50:34.492958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}